In many respects, hydroxychloroquine, an off-patent antimalarial used for autoimmune diseases, with decades of safety data, and with data suggesting in vitro
Abstract Background Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19)
We hypothesized that a systematic review
A total of 642 articles were obtained from five databases, 271 duplicates and 319 articles that did not meet the inclusion criteria were excluded
10
An electronic literature search was conducted during the months of June and July, 2020 for articles on HCQ as a treatment option for COVID-19
Trial design and participants
For (pre-exposure) prophylaxis in pregnancy, where vaccines may be contraindicated, the alternative of hydroxychloroquine has been advocated
The standard care included paracetamol, Vitamin C, zinc, hydroxychloroquine, doxycycline, azithromycin, amoxycillin with potassium clavulanate and favipiravir as per the clinical condition of the patient along with the infection prevention and control practices
People with COVID-19 often have symptoms in the long term (ie, long COVID), including fatigue, breathlessness, and neurocognitive difficulties
Search strategy and selection criteria
Although newer medications have largely replaced HCQ in the treatment of malaria, the drug continues to be a common
Recent evidences have focused its major role in glucose hemostasis in hyperglycemic patients
However, large-scale studies examining the long-term effects of hydroxychloroquine on the development of kidney disease in patients with rheumatoid arthritis are lacking
[3]
Discussion
reported a correlation between a lower mean hydroxychloroquine whole blood level and thrombotic events (720 vs
Hydroxychloroquine was found could potentially induce or intensify AKI by increasing lysosomal pH and inhibiting autophagy, because it has been demonstrated that Hydroxychloroquine inhibits autophagic flux by impairing autophagosome-lysosome fusion